Výsledky vyhľadávania - "Skin Neoplasms/immunology [MeSH]"

Die Bedeutung von Sarkopenie für die immunvermittelte Toxizität bei Patienten mit malignem Melanom unter einer Immuncheckpoint-Inhibition

Autori: Holtorf, Christian Mengoni, Miriam Tüting, Thomas a ďalší

Zdroj: Dermatologie (Heidelb)

Predmety: ddc:610, Psoasmuskulatur, Aged, 80 and over [MeSH], Aged [MeSH], Psoas Muscles/diagnostic imaging [MeSH], Skin Neoplasms/drug therapy [MeSH], Tomography, X-Ray Computed [MeSH], Sarcopenia/diagnostic imaging [MeSH], Originalien, Male [MeSH], Sarcopenia/chemically induced [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Sarkopenie, Malignes Melanom, Melanoma/pathology [MeSH], Toxicity, Muscular atrophy, Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Female [MeSH], Immuncheckpoint-Inhibition, Toxizität, Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Psoas Muscles/pathology [MeSH], Immune checkpoint inhibitors, Malignant melanoma, Melanoma/immunology [MeSH], Psoas muscles

Popis súboru: application/pdf

Prístupová URL adresa: https://nbn-resolving.org/urn:nbn:de:hbz:294-117574
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/11757
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/11757/AlterMareike14082024.pdf
https://repository.publisso.de/resource/frl:6515383

Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates

Autori: Jürgen C. Becker Andreas Stang David Schrama a ďalší

Zdroj: Am J Clin Dermatol

Predmety: Carcinoma, Merkel Cell, ddc:610, Review Article, Carcinoma, Merkel Cell/therapy [MeSH], Humans [MeSH], Carcinoma, Merkel Cell/epidemiology [MeSH], Skin Neoplasms/immunology [MeSH], Skin Neoplasms/therapy [MeSH], Carcinoma, Merkel Cell/immunology [MeSH], Skin Neoplasms/pathology [MeSH], Carcinoma, Merkel Cell/diagnosis [MeSH], Merkel cell polyomavirus/immunology [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Skin Neoplasms/epidemiology [MeSH], Skin Neoplasms, Merkel cell polyomavirus, Humans, Immune Checkpoint Inhibitors

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38649621
https://repository.publisso.de/resource/frl:6507564
https://opus.bibliothek.uni-wuerzburg.de/files/39746/40257_2024_Article_858.pdf
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-397461
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/39746
https://doi.org/10.1007/s40257-024-00858-z

CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients

Autori: Strobel, Sophia B. Machiraju, Devayani Wiecken, Melanie a ďalší

Zdroj: Cancer Immunol Immunother
Cancer Immunology, Immunotherapy, Vol 74, Iss 2, Pp 1-10 (2025)

Predmety: Male, Adult, Aged, 80 and over, IgM, Skin Neoplasms, IgG, Research, Antibodies, Viral/immunology [MeSH], Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Skin Neoplasms/blood [MeSH], Skin Neoplasms/drug therapy [MeSH], Immunotherapy/methods [MeSH], Survival, Male [MeSH], Hepatitis/immunology [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], CMV, Cytomegalovirus/immunology [MeSH], Peripheral Immune cells, Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Antibodies, Viral/blood [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Cytomegalovirus Infections/immunology [MeSH], Melanoma/blood [MeSH], Middle Aged [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Melanoma/immunology [MeSH], Hepatitis, Immunotherapy, Prognosis [MeSH], Hepatitis/etiology [MeSH], Immunoglobulin G/blood [MeSH], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cytomegalovirus, Middle Aged, Prognosis, Antibodies, Viral, Immunoglobulin G, Cytomegalovirus Infections, Humans, Female, Immune Checkpoint Inhibitors, RC254-282, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39751902
https://doaj.org/article/a197d0c8bedc4374af525c6e7ba3d123
https://repository.publisso.de/resource/frl:6507066

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Autori: Grote, Carolin Bohne, Ann-Sophie Blome, Christine a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Surveys and Questionnaires [MeSH], Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Ipilimumab/administration, Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Quality of Life [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], HrQoL, Female [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Ipilimumab/adverse effects [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], ICI, Immune Checkpoint Inhibitors/therapeutic use [MeSH], Distress thermometer, Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Ipilimumab/therapeutic use [MeSH], IBDQ-D, SF-36, Nivolumab/administration, Nivolumab/therapeutic use [MeSH], Middle Aged, Ipilimumab, Nivolumab, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Prospective Studies, Immune Checkpoint Inhibitors, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39387946
https://repository.publisso.de/resource/frl:6497979

Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockade

Autori: Miriam Mengoni Andreas Dominik Braun Mattes Simon Hinnerichs a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Middle Aged, Prognosis, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Body Composition, Humans, Female, Muscle, Skeletal, Tomography, X-Ray Computed, Melanoma, Immune Checkpoint Inhibitors, Melanoma/therapy [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Muscle, Skeletal/diagnostic imaging [MeSH], Skin Neoplasms/drug therapy [MeSH], Low skeletal muscle mass, Tomography, X-Ray Computed [MeSH], Male [MeSH], Muscle, Skeletal/pathology [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Melanoma/mortality [MeSH], Body Composition [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Immunotherapy, Prognosis [MeSH], Skin Neoplasms/mortality [MeSH], Body composition, Retrospective Studies, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38796605
https://repository.publisso.de/resource/frl:6492801

The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression

Autori: Christina Jessen Julia K. C. Kreß Apoorva Baluapuri a ďalší

Zdroj: Oncogene

Predmety: Male, 0301 basic medicine, Lung Neoplasms, Datasets as Topic, Adenocarcinoma of Lung, Cell Line, Tumor [MeSH], Immunity, Innate/genetics [MeSH], Gene Expression Regulation, Neoplastic/immunology [MeSH], Melanoma, Lung Neoplasms/genetics [MeSH], Tumor Escape/genetics [MeSH], NF-E2-Related Factor 2/metabolism [MeSH], NF-E2-Related Factor 2/genetics [MeSH], Activating Transcription Factor 4/metabolism [MeSH], Gene Knockout Techniques [MeSH], Male [MeSH], Adenocarcinoma of Lung/genetics [MeSH], Melanoma/pathology [MeSH], Lung Neoplasms/immunology [MeSH], Microphthalmia-Associated Transcription Factor/metabolism [MeSH], Skin Neoplasms/immunology [MeSH], Disease Models, Animal [MeSH], Female [MeSH], Oncogenes, Melanoma/genetics [MeSH], Datasets as Topic [MeSH], Humans [MeSH], Gene Knockdown Techniques [MeSH], Cell Differentiation/genetics [MeSH], Adenocarcinoma of Lung/immunology [MeSH], Skin Neoplasms/pathology [MeSH], Animals [MeSH], Mice [MeSH], Article, Skin Neoplasms/genetics [MeSH], Melanoma/immunology [MeSH], Lung Neoplasms/pathology [MeSH], Dinoprostone/metabolism [MeSH], Cyclooxygenase 2/metabolism [MeSH], Adenocarcinoma of Lung/pathology [MeSH], Dinoprostone, Gene Knockout Techniques, Mice, 03 medical and health sciences, Cell Line, Tumor, Animals, Humans, ddc:610, Microphthalmia-Associated Transcription Factor, 0303 health sciences, Cell Differentiation, Activating Transcription Factor 4, Immunity, Innate, 3. Good health, Gene Expression Regulation, Neoplastic, Disease Models, Animal, Cyclooxygenase 2, Gene Knockdown Techniques, Female, ddc:570

Popis súboru: application/pdf

Prístupová URL adresa: https://www.nature.com/articles/s41388-020-01477-8.pdf
https://pubmed.ncbi.nlm.nih.gov/32978520
https://ora.ox.ac.uk/objects/uuid:86dc57a2-0392-477d-b201-b1d92016a4a8
https://doi.org/10.1038/s41388-020-01477-8
https://repository.publisso.de/resource/frl:6471342
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-235064
https://opus.bibliothek.uni-wuerzburg.de/files/23506/s41388-020-01477-8.pdf
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/23506
https://doi.org/10.1038/s41388-020-01477-8

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

Autori: Anne Fröhlich Dennis Niebel Simon Fietz a ďalší

Zdroj: Cancer Immunol Immunother

Predmety: Adult, Male, 0301 basic medicine, Melanoma/therapy [MeSH], Costimulatory and Inhibitory T-Cell Receptors/antagonists, Disease Progression [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents, Immunological/pharmacology [MeSH], Advanced melanoma, Oncolytic Virotherapy/methods [MeSH], Original Article, Neoplasm Staging [MeSH], Immunotherapy/methods [MeSH], Male [MeSH], Melanoma/pathology [MeSH], Targeted therapy, Skin Neoplasms/immunology [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Drug Resistance, Neoplasm/drug effects [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Drug Resistance, Neoplasm/immunology [MeSH], Melanoma/mortality [MeSH], Herpesvirus 1, Human [MeSH], Melanoma/immunology [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Biological Products/administration, Immunotherapy, Skin Neoplasms/mortality [MeSH], Skin Neoplasms/therapy [MeSH], Talimogene laherparepvec, Costimulatory and Inhibitory T-Cell Receptors/immunology [MeSH], Acquired resistance, Herpesvirus 1, Human, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Costimulatory and Inhibitory T-Cell Receptors, Humans, Melanoma, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Oncolytic Virotherapy, Biological Products, Middle Aged, Progression-Free Survival, 3. Good health, Drug Resistance, Neoplasm, Disease Progression, Female, Follow-Up Studies

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00262-020-02487-x.pdf
https://pubmed.ncbi.nlm.nih.gov/32052079
https://link.springer.com/content/pdf/10.1007/s00262-020-02487-x.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183503
https://pubmed.ncbi.nlm.nih.gov/32052079/
https://link.springer.com/article/10.1007/s00262-020-02487-x
https://www.ncbi.nlm.nih.gov/pubmed/32052079
https://repository.publisso.de/resource/frl:6470336